doi: 10.5483/BMBRep.2020.53.1.279 72 LiQLiuYSunM
Decision factors: Weight loss goals: Want maximum weight loss and can tolerate side effects: Tirzepatide (Zepbound) shows ~4% greater weight loss than semaglutide on average Want proven cardiovascular benefits: Semaglutide has demonstrated 20% reduction in major cardiovascular events in the SELECT trial Want to try oral option: Oral semaglutide (Rybelsus) for diabetes, though weight loss is less than injectable Side effect sensitivity: Some people tolerate one better than the other
This can slow progress and increase the risk of fatigue, weakness, constipation, and muscle loss
If successful, the findings could pave the way for larger clinical trials and potential FDA consideration for an approved drug treatment for lymphedema
Data limitations: We have very limited data on transfer to breast milk
Mosenzon O, Blicher TM, Rosenlund S, et al